



Trends in  
**Medical Research**

ISSN 1819-3587



Academic  
Journals Inc.

[www.academicjournals.com](http://www.academicjournals.com)

## **Creeping Enigma of Head and Neck Cancers**

<sup>1</sup>Abhishek Singh, <sup>2</sup>V. Chendil and <sup>2</sup>Iqbal Ahmed

<sup>1</sup>Department of Oral Medicine and Radiology, Government Dental College and Research Institute, India

<sup>2</sup>Department of Radiotherapy, Bangalore Medical College and Research Institute, India

*Corresponding Author: Abhishek Singh, Department of Oral Medicine and Radiology, Government Dental College and Research Institute, Bangalore-560002, Karnataka, India*

### **ABSTRACT**

Pain is one of the most common presenting complaints in patients diagnosed with advanced head and neck cancers occurring in about thirds of the patients at the time when they are first diagnosed in the initial stages of the disease process. Among these, about half of the patients die within five years from the day of diagnosis while the ones who survive are left with significant morbidity. Cancer-associated pain is one of the most common situations difficult to manage in a significant number of head and neck cancer affected patients. Despite all the advances in the understanding, diagnosis and the treatment modalities available for the treatment of cancer associated pain, a significant fraction of patients are left to bear considerable pain owing to the lack of an exact criteria for the evaluation of pain, reluctance of the health care providers regarding the use of opioids and the reservation of advanced treatment modalities for the management of pain only in its advanced or terminal stages. The aim of this paper is to highlight the varying aetiologies and patho-physiologies of the head and neck cancer associated pain and more than that the need for an effective pain management protocol to be followed in the management of the variable expressions of this type of pain in patients who are left to suffer agony of pain despite the availability of voluminous literature regarding the understanding of cancer associated pain.

**Key words:** Head and neck cancer pain, nociceptive, neuropathic, algesia

### **INTRODUCTION**

The International association for the study of pain defines pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage (Caimi and Cymet, 2006; Besson, 1997).

Pain, in fact, is described to be a protective sensation and reflex of the body as it alerts an individual towards a physical injury and some disease process going on in the body as described by Sherrington as the physical adjunct of an imperative protective reflex.

**Diagnosing head and neck cancer associated pain-a diagnostic dilemma:** Assessment of the head and neck cancer associated pain is often considered a challenging task for the health-care providers owing to its multi-factorial aetiology as well as the modification of the essential pain components, objective as well as subjective, depending on the actual sensation of the pain as well as the reaction of the patient due to a variable perceptive component secondary to a number of defined and can't be defined criteria (Caimi and Cymet, 2006; Besson, 1997). The majority of the

head and neck cancer associated pain is because of the direct impact of the growing neoplasm accounting roughly around 83% while the rest of the 17% of the cases reporting with pain due to the secondary effects of anti-cancer therapeutic regimens (Aird *et al.*, 1983).

**Pain perception versus pain reaction:** Pain is composed of two essential components-the first component being the actual sensation as perceived by the central nervous system and the second, being the reactionary component, a subjective component that actually influences the patient's perception of pain (Caimi and Cymet, 2006; Besson, 1997). The psycho-social aspects, depression, anxiety and fear, mental isolation, other unrelieved symptoms and the actual sensation of pain itself in this particular group of patients, all lead to the exacerbation of the total experience of pain (Caimi and Cymet, 2006; Besson, 1997).

**Why to know the biology of cancer pain?:** The exact assessment of the type and cause of the pain becomes important since the former helps in providing the appropriate symptomatic therapy for the pain while the latter helps in the appropriate treatment required for controlling the underlying causative disease process (Caimi and Cymet, 2006; Besson, 1997).

**Emotional component of pain:** The emotional component of the pain, an essential component of head and neck cancer associated pain, is explained on the basis of the fact that on their way to the central nervous system, important collaterals from the pain pathway are given to the components of the limbic system, the so-named amygdala complex (Caimi and Cymet, 2006; Besson, 1997).

**Algesia and hyperalgesia:** Also, the perception of the pain is at two distinct levels. The first perception of the pain sensation is at the sub-cortical level at the level of the thalamus and this perception of the pain is responsible for the sensation of crude pain. The higher level of pain perception is at the cortical level which gives the final perception of the actual sensation of pain with all its distinctive characteristics. Sometimes, the pain threshold gets lowered, the exaggerated sensation and perception of pain being referred to as hyperalgesia (Grond *et al.*, 1996).

Further, the different types of pain include the fast and slow pain carried by the A-delta and C fibers respectively. The fast pain is perceived immediately after a trauma or injury in a well-defined anatomic region either due to the noxious stimulation of the peripherally located bare nerve endings or due to neural compression secondary to pressure effects owing to cancer associated growths or oedema due to secondary infections around a nerve trunk, being carried by the A-delta fibers, taken over by a more diffuse, dull and intense pain sensation, carried by the C fibers (Grond *et al.*, 1996).

The pain sensation perceived also can be superficial or deep, based on the structures from where the pain sensation arises with the pain sensation arising from the deeper structures like muscle, bone or periosteum and tendons being called deep pain, poorly localised and the one arising from the superficial structures as skin being referred to as superficial pain and usually well-localised, based on the anatomic level of invasion of the cancer associated growths.

**What the international association for the study of pain says?:** The scheme proposed by the International Association for the Study of Pain categorizes pain according to five different axes-the location of pain, involved organ or tissue, the temporal pattern of pain, pain intensity and the time

since the onset of pain and the prime factor-the etiological factor/factors behind the origin of pain (Caimi and Cymet, 2006).The IASP scheme, however, does not distinguish formally cancer pain from the non-malignant causes of chronic pain or do other diagnostic schema advanced by the US Department of Health and Human Services and the World Health Organisation.

The classification of cancer pain may and does have important diagnostic and therapeutic implications; hence, a distinct taxonomy of cancer pain is highly warranted for the effective assessment, gradation and management of this unique group of multi-aetiological pain in the advanced stages of cancer management (Besson, 1997; Ventafridda and Caraceni, 1991).

### **Various schemes for classifying head and neck cancer pain**

**Aetiologic classification:** Based on the proposed aetiology of the causation of head and neck cancer associated pain, it can be classed as the one which is primarily caused by cancer, either because of compression or infiltration of pain sensitive structures, invasion of bone, nerve and muscle; or the pain that is caused as a consequence of the various treatment modalities used for treating cancer; pain caused due to disabilities in the form of post-herpetic neuralgia and pain that is un-related to cancer or the one arising as an after-math of the therapeutic approaches used for treating cancer or the pain that is perceived as a result of some other concurrent pathology in the form of arthritis, migraine or neuropathy etc. (Julius and Basbaum, 2001).

**Patho-physiologic classification:** Based on the patho-physiology of the pain sensation, it can, further, be classed as nociceptive and neuropathic or the one that is of confounding or mixed pathology along with the one that is purely psychogenic in origin.

**Temporal classification:** Based on the temporal basis of pain, it can be classed as acute, breakthrough or chronic pain (Merskey and Bogduk, 1994).

**Classification based on the severity of pain:** Last but not the least, pain sensation perceived is graded and based on the severity of pain as mild, moderate or severe (Ventafridda and Caraceni, 1991; Merskey and Bogduk, 1994; Stute *et al.*, 1997).

Most of the head and neck cancer related pain is caused due to the effects of cancer itself. The uncoordinated growth pattern revealed by the growing neoplasm often leads to pressure effects on the subjacent structures and infiltrate the pain sensitive structures or invade the bone, nerve and muscle leading to the onset of pain sensation (Grond *et al.*, 1996).

Locally invasive and erosive cancers directly produce tissue destruction and nerve compression evoking the pain sensation (Portenoy, 1992; Gebhart, 1995).

Recent studies have indicated pain mediating inflammatory cytokines to be either released from the growing tumor or from the surrounding tissues in response to tumor invasion and metastasis as in cases of secondaries in jaw bones from the metastatic spread of cancers of the breast and prostate (Mercadante, 1997; Coleman, 2001).

Again, injury to the nerves, central or peripheral, results in multiple alterations in the pain mediating pathways in addition to the direct irritation of the bare nerve endings coming in contact with the pain mediating cytokines (Julius and Basbaum, 2001; Lee *et al.*, 2004; Honore *et al.*, 2000). Also, sometimes, the depolarisation threshold gets lowered and nerve impulses start generating spontaneously, so-called hyperalgesia as already described. This occurs partially via calcium influx into the cells, a factor considered significant since many analgesic medications act

by blocking these calcium channels at the level of the spinal cord. Activation of the normally inactive NMDA-N-methyl D-aspartate receptors is another crucial step that amplifies the pain response-the NMDA receptors being other important targets for the cancer pain relieving analgesic medications (Bonica, 1979).

**Iatrogenic cancer pain:** Another important cause of head and neck cancer associated pain is the pain that is produced as a consequence of the various treatment modalities being used in the treatment of the primary pathologic process (Macrae, 2001). These types of iatrogenic pain sensations can be perceived either in the form of acute pain or the discomfort following surgery or other invasive procedures or in the form of various post-surgical chronic pain syndromes and pain due to unintentional severing of peripheral nerves (Portenoy, 1992; Macrae, 2001).

The use of radio-chemo-therapies can, also, lead to severe type of pain perceived as a result of radio-chemo-therapy induced mucositis, secondary opportunistic infections in the form of candida and herpes simplex viral infections and peripheral neuropathy (Epstein *et al.*, 1999; Epstein and Stewart, 1993; Modi *et al.*, 2000). Oral mucositis is a therapy and rate-limiting complication of cancer chemotherapy as well as head and neck radiation therapy.

Moreover, many chemotherapeutic agents are well known for their adverse drug effects in the form of peripheral neuropathy (Martin and Hagen, 1997; Grond *et al.*, 1999). Radiation therapy may also, compromise blood supply to vital tissue structures, decrease healing capacity, injure soft tissues and neuronal structures resulting in mucositis, osteoradionecrosis and peripheral neuropathies (Epstein *et al.*, 1999; Epstein and Stewart, 1993; Grond *et al.*, 1999).

To make conditions even worse, musculoskeletal pain is rather a common complication seen in patients following treatment for head and neck cancers (Mercadante, 1997; Coleman, 2001; Epstein *et al.*, 1997; Coleman, 1997). The common aetiologies for pain perceived in such patients include the effect of the tumor on the underlying and subjacent structures, pressure effects, post-surgical and post-radiotherapy complications including various grades of jaw resections, secondary scarring and fibrosis and contractures along with secondary temporo-mandibular joint changes (Epstein *et al.*, 1999; Epstein and Stewart, 1993).

In the end to summarise, it can be said that a significant number of cancer patients often have more than one identifiable patho-physiologic type of cancer associated pain. One study highlighted that a group of 31% of cancer affected patients suffered from mixed nociceptive and neuropathic types of pain (Honore *et al.*, 2000). In another similar study conducted by Ashby and colleagues, 79% of the patients suffered from two or more patho-physiologic types of pain (Caimi and Cymet, 2006; Besson, 1997; Stute *et al.*, 1997; Portenoy, 1992).

**Psychogenic pain:** A Grave confounder-Psychogenic pain is another important cause of pain often making the life of cancer patients even more miserable and arrived at; largely by the diagnosis of exclusion (Payne, 1997). Although a crude task, psychological basis of pain alone can hardly be associated with most of the cancer associated pains. Conversely, however, the role of psychogenic pain as a compounding and aggravating component affecting the patient's actual perception of pain can again hardly be ruled-out.

**Breakthrough pain:** A therapy-associated concept of pain-Another significant term used in descriptions of cancer associated pains is the breakthrough pain that is the pain that indicates the flare-up of discomfort in patients in whom the base-line level of pain is well-controlled by the round-the-clock analgesic regimen (Patt and Ellison, 1998; Caraceni *et al.*, 2004; Portenoy *et al.*, 1999).

The severity of cancer pain is of help in reflecting the size of tumor, its localisation and the extent of tissue destruction. The mechanism of pain is also an important determinant in the characterisation of pain as metastatic bone lesions and neural injuries are notoriously more severe than the pain arising as a consequence of a slow growth of a neoplasm (Mercadante, 1997; Coleman, 2001; Coleman, 1997).

**Head and neck cancer pain-a dynamic clinical experience:** Another significant factor affecting the management of head and neck cancer associated pain is its dynamic nature with the intensity of pain fluctuating during the course of the disease as well as the institution of treatment, thereby, making it mandatory to re-evaluate periodically and determine the severity of pain.

Information regarding the pain including its localisation, character, severity, onset and duration, temporal pattern, relieving and aggravating factors, associated symptoms and previous analgesic therapy and any history of prior anti-cancer treatment should well be obtained (Besson, 1997). The patient's psychological state including the presence of anxiety, fear or depression should also be assessed (Payne, 1997). The most important parts of the physical systems include the evaluation of neurological and musculoskeletal systems.

Serum tumor markers may be of significance in the assessment of the exact extent of the tumor along with a high prognostic significance and the detection of any secondary or metastasis in association with the primary tumor or any recurrence of the tumor. Various imaging modalities can also be used to arrive at a particular cause of cancer associated pain depending on the situation (Foley, 1999).

## CONCLUSION

The aim of this paper is to highlight the varying aetiologies and patho-physiologies of the head and neck cancer associated pain and more than that the need for an effective pain management protocol to be followed in the management of the variable expressions of this type of pain in patients who are made and left to suffer and live a life full of agony of pain despite the availability of voluminous literature regarding the understanding of cancer associated pain (Caimi and Cymet, 2006; Besson, 1997; Coyle *et al.*, 1990).

## ACKNOWLEDGMENT

We thank all the people who directly and indirectly contributed for the literature search as it required intense efforts from the people outside our Department including the staff of the libraries of Bangalore Medical College and Research Institute and Associated Hospitals and National Institute of Mental Health and Associated Sciences and St. John Hospital, Bangalore.

## REFERENCES

- Aird, D.W., J. Bihari and C. Smith, 1983. Clinical problems in the continuing care of head and neck cancer patients. *Ear Nose Throat J.*, 62: 230-243.
- Besson, J.M., 1997. The complexity of physiopharmacologic aspect of pain. *Drugs*, 53: 1-9.
- Bonica, J.J., 1979. Introduction to Management of Pain in Advanced Cancer. In: *International Symposium on Pain of Advanced Cancer*, Bonica, J.J. and V. Ventafridda (Eds.). Raven Press, New York, USA., ISBN-13: 9780890042700, pp: 115-130.
- Caimi, P. and T.C. Cymet, 2006. As if the cancer wasn't enough: Understanding and treating the pain that comes with cancer. *Compr. Ther.*, 32: 176-181.

- Caraceni, A., C. Martini, E. Zecca, R.K. Portenoy and M.A. Ashby *et al.*, 2004. Breakthrough pain characteristics and syndromes in patients with cancer pain: An international survey. *Palliative Med.*, 18: 177-183.
- Coleman, R.E., 1997. Skeletal complications of malignancy. *Cancer*, 80: 1588-1594.
- Coleman, R.E., 2001. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. *Cancer Treat. Rev.*, 27: 165-176.
- Coyle, N., J. Adelhardt, K.M. Foley and R.K. Portenoy, 1990. Character of terminal illness in the advanced cancer patient: Pain and other symptoms during the last four weeks of life. *J. Pain Symptom Manage.*, 5: 83-93.
- Epstein, J.B. and K.H. Stewart, 1993. Radiation therapy and pain in patients with head and neck cancer. *Eur. J. Cancer Part B: Oral Oncol.*, 29: 191-199.
- Epstein, J.B., E. van der Meij, M. McKenjie, F. Wong, M. Lepawsky and P. Stevenson-Moore, 1997. Post-radiation osteonecrosis of the mandible: A long-term follow-up study. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol.*, 83: 657-662.
- Epstein, J.B., S. Emerton, D.A. Kolbinson, N.D. Le, N. Phillips, P. Stevenson-Moore and D. Osoba, 1999. Quality of life and oral function following radiotherapy for head and neck cancer. *Head Neck*, 21: 1-11.
- Foley, K.M., 1999. Advances in cancer pain. *Arch. Neurol.*, 56: 413-417.
- Gebhart, G., 1995. Visceral Pain. In: *Progress in Pain Research and Management*, Gebhart, G. (Ed.). IASP Press, Seattle, WA., USA., pp: 543-556.
- Grond, S., D. Zech, C. Diefenbach, L. Radbruch and K.A. Lehmann, 1996. Assessment of cancer pain: A prospective evaluation in 2266 cancer patients referred to a pain service. *Pain*, 64: 107-114.
- Grond, S., S. Radbruch, T. Meuser, R. Sabatowski, G. Loick and K.A. Lehmann, 1999. Assessments and treatment of neuropathic cancer pain following WHO guidelines. *Pain*, 79: 15-20.
- Honore, P., S.D. Rogers, M.J. Schwei, J.L. Salak-Johnson and N.M. Luger *et al.*, 2000. Murine models of inflammation, neuropathic and cancer pain, each generating a unique set of neurochemical changes in the spinal cord and sensory neurons. *Neuroscience*, 98: 585-598.
- Julius, D. and A.I. Basbaum, 2001. Molecular mechanisms of nociception. *Nature*, 413: 203-210.
- Lee, B.N., R. Dantzer, K.E. Langley, G.J. Bennett and P.M. Dougherty *et al.*, 2004. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. *Neuroimmunomodulation*, 11: 279-292.
- Macrae, W.A., 2001. Chronic pain after surgery. *Br. J. Anaesthesia*, 87: 88-98.
- Martin, L.A. and N.A. Hagen, 1997. Neuropathic pain in cancer patients: Mechanisms, syndromes and clinical controversies. *J. Pain Symptom Manage.*, 14: 99-117.
- Mercadante, S., 1997. Malignant bone pain: Pathophysiology and treatment. *Pain*, 69: 1-18.
- Merskey, H. and N. Bogduk, 1994. *Classification of Chronic Pain*. 2nd Edn., IASP Press, Seattle.
- Modi, S., J. Pereira and J.R. Mackey, 2000. The cancer patients with chronic pain due to herpes zoster. *Curr. Pain Headache Rep.*, 4: 429-436.
- Patt, R.B. and N.M. Ellison, 1998. Breakthrough pain in cancer patients: Characteristics, prevalence and treatment. *Oncology*, 12: 1035-1046.
- Payne, R., 1997. Mechanisms and management of bone pain. *Cancer*, 80: 1608-1613.
- Portenoy, R.K., 1992. Cancer pain: Pathophysiology and syndromes. *Lancet*, 339: 1026-1031.

- Portenoy, R.K., D. Payne and P. Jacobsen, 1999. Breakthrough pain: Characteristics and impact in patients with cancer pain. *Pain*, 81: 129-134.
- Stute, P., M. Soukup, M. Menzel, R. Sabatowski and S. Grond 1997. Analysis and treatment of different types of neuropathic cancer pain. *J. Pain Symptom Manage.*, 26: 1123-1130.
- Ventafriida, V. and A. Caraceni, 1991. Cancer pain classification: A controversial issue. *Pain*, 46: 1-2.